Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

The pharmaceutical manufacturing sector in Japan is poised for significant growth, with the market expected to surge from a valuation of US$ 34.7 billion in 2024 to a projected US ...

With a market projected to reach US$ 2,301.6 billion by 2032, the pharmaceutical manufacturing industry is not just growing—it’s evolving. The convergence of digital innovation, changing disease ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...